Indication
Treatment of insomnia in children and adolescents aged 2-18 with autism spectrum disorder (ASD) and / or Smith-Magenis syndrome, where sleep hygiene measures have been insufficient.

Medicine details

Medicine name:
melatonin (Slenyto)
SMC ID:
SMC2168
Pharmaceutical company
Flynn Pharma Ltd
BNF chapter
Central nervous system
Submission type
Full
Status
Advice due date:
09 September 2019
SMC meeting date:
06 August 2019
Patient group submission deadline:
01 July 2019